“超级真菌”耳念珠菌研究进展  

Recent progress of the study on the “superbug fungus” Candida auris:a review

作　　者：黄倩 邴健 岳慧珍 黄广华 魏羽佳 HUANG Qian;BING Jian;YUE Hui-Zhen;HUANG Guang-Hua;WEI Yu-Jia(Dermatology Department,Affiliated Hospital of Guizhou Medical University,Guiyang,Guizhou 550004,China;State Key Laboratory of Mycology,Institute of Microbiology,Chinese Academy of Sciences,Beijing 100101,China)

机构地区：[1]贵州医科大学附属医院皮肤科,贵州贵阳550004 [2]中国科学院微生物研究所真菌学国家重点实验室,北京100101

出　　处：《菌物学报》2018年第10期1278-1286,共9页Mycosystema

基　　金：贵州省优秀科技教育人才省长专项资金[(2011)28号];国家临床重点专科建设项目(皮肤科);卫办医政函[(2012)649号]~~

摘　　要：耳念珠菌Candida auris也被称为"超级真菌",是近年来出现的一种人体病原真菌新物种,临床分离株通常具有多重耐药和高致死率等特征。2009年日本首次报道耳念珠菌之后,其感染病例在多个国家呈现出爆发式增长。目前已报道的病例分布在全球五大洲27个国家,包括中国。耳念珠菌感染给临床诊断和防控以及人类健康带来了巨大的挑战。本文从该菌临床分离菌株的生物学、遗传变异分化及耐药特征等方面入手,围绕分子流行病学、基因组特征、毒性因子和耐药性等方面系统地综述了近年来国内外取得的相关进展,并探讨了我国耳念珠菌感染的诊断、治疗和预防的措施。The ＂superbug fungus＂ Candida auris is a globally emerged pathogen that is often associated with multidrug resistance and high mortality. Since the first isolation in Japan in 2009, infections caused by this fungus have been reported in at least 27 countries on five continents, including China. Its wide spread and dramatically increased clinical cases lead to an intensive attention from both the clinical and the basic research communities worldwide. In this paper, we review recent progress of both clinical and biological aspects of C. auris. We focus on the global molecular epidemiology, genomic and virulent features, and drug resistance of clinical isolates. In addition, we discuss the potential measures for the diagnosis, treatment and control of C. auris infections in China.

关 键 词：耳念珠菌 多重耐药 毒性 分子流行病学 

分 类 号：R379.4[医药卫生—病原生物学]